Avalon Announces the Commencement of Feasibility Study at Lake Superior Lithium Project, Ontario
Avalon Pivots to Engineering Execution as Massive Funding Gap Looms Over Multi-Billion Dollar Ontario Lithium Ambitions

On January 19, 2026, Avalon announced the commencement of Feasibility Study (FS) engineering for its Lake Superior Lithium Hydroxide Processing Project in Thunder Bay, Ontario. The company has engaged Nordmin Engineering Ltd. as the lead consultant, supported by Metso, Primero Americas, and Krech Ojard & Associates. The FS is targeted for completion in the first half of 2027. The announcement recaps the September 2024 PEA, which highlighted an after-tax NPV of $4.1 billion and a 48% IRR, predicated on an initial capital cost of $1.2 billion.
The news is a necessary step in the development cycle but does not alter the fundamental risk profile of the company. - De-risking vs. Dilution: While hiring top-tier consultants like Metso and Nordmin adds credibility, the timeline (H1 2027) suggests a long "quiet period" regarding the refinery's definitive economics. - Validation of Previous Raise: This move validates the use of proceeds from the $18.65 million financing closed in October 2025. Management is following through on its promise to advance the project to construction readiness. - Economic Scale Dissonance: The market remains skeptical of the $4.1B NPV. The material impact of "commencing a study" is limited when the company still faces a $1.2 billion capital expenditure hurdle—nearly 24 times its current market capitalization.
Avalon is transitioning from a diversified explorer to a mid-stream processor. - Flagship Project: The Lake Superior Lithium Hydroxide Processing Project (Thunder Bay Refinery). It aims to produce 30,000 tonnes per year of battery-grade lithium hydroxide. - Secondary Asset: The Nechalacho Rare Earth Elements project in NWT. This is one of the highest-grade "heavy" rare earth deposits globally, currently being "refreshed" with new technology to improve recovery rates (90%+ claimed in bench tests).